Lipoxin signaling in neutrophils and their role in periodontal disease

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 73, Issue 3-4, 2005, Pages 289-299

  Kantarci, Alpdogan ^a   Van Dyke, Thomas E ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 EPI 16 PHENOXY 4 FLUOROLIPOXIN A 4; 15 EPILIPOXIN A 4; ACETYLSALICYLIC ACID; ASPIRIN TRIGGERED LIPOXIN; CORTICOSTEROID; ESSENTIAL FATTY ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LIPOXIN; LIPOXIN A; NONSTEROID ANTIINFLAMMATORY AGENT; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CELL INTERACTION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; LEUKOCYTE; MUCOSA; NEUTROPHIL; NONHUMAN; PERIODONTAL DISEASE; PERIODONTITIS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TISSUE INJURY;

EID: 24344510837     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2005.05.019     Document Type: Article

References (106)

1. S.S. Socransky, and A.D. Haffajee Periodontal microbial ecology Periodontol 2000 38 2005 135 187
2. A.D. Haffajee, and S.S. Socransky Microbiology of periodontal diseases: introduction Periodontol 2000 38 2005 9 12
3. W. Beertsen, C.A. McCulloch, and J. Sodek The periodontal ligament: a unique multifunctional connective tissue Periodontol 2000 13 1997 20 40
4. S. Offenbacher Periodontal diseases: pathogenesis Ann. Periodontol. 1 1 1996 821 878
5. K.S. Kornman, R.C. Page, and M.S. Tonetti The host response to the microbial challenge in periodontitis: assembling the players Periodontol 2000 14 1997 33 53
6. A. Kantarci, K. Oyaizu, and T.E. Van Dyke Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis J. Periodontol. 74 1 2003 66 75
7. D.F. Kinane, and G.D. Lowe How periodontal disease may contribute to cardiovascular disease Periodontol 2000 23 2000 121 126
8. V. Kumar, A.K. Abbas, and N. Fausto V. Kumar A.K. Abbas N. Fausto Robbins and Cotran Pathologic Basis of Disease seventh ed. 2005 Elsevier Saunders Philadelphia, PA 47 86
9. C.N. Serhan, and E. Oliw Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways J. Clin. Invest. 107 12 2001 1481 1489
10. K. Wada Inosine monophosphate and aspirin-triggered 15-epi-lipoxin A4 act in concert to regulate neutrophil trafficking: additive actions of two new endogenous anti-inflammatory mediators, J. Hematother. Stem Cell Res. 10 1 2001 75 79
11. D.S. Kelley Modulation of human immune and inflammatory responses by dietary fatty acids Nutrition 17 7-8 2001 669 673
12. P. Benito The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans Lipids 36 3 2001 221 227
13. M. Murakami Regulatory functions of phospholipase A2 Crit. Rev. Immunol. 17 3-4 1997 225 283
14. M. Hamberg, and B. Samuelsson Prostaglandins in human seminal plasma. Prostaglandins and related factors 46 J. Biol. Chem. 241 2 1966 257 263
15. M. Hamberg, J. Svensson, and B. Samuelsson Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides Proc. Natl. Acad. Sci. USA 72 8 1975 2994 2998
16. Y. Yoshikai Roles of prostaglandins and leukotrienes in acute inflammation caused by bacterial infection Curr. Opin. Infect. Dis. 14 3 2001 257 263
17. B. Samuelsson An elucidation of the arachidonic acid cascade. Discovery of prostaglandins, thromboxane and leukotrienes Drugs 33 Suppl. 1 1987 2 9
18. G.A. Higgs Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis Prostaglandins 12 5 1976 749 757
19. J.R. Vane The mode of action of aspirin and similar compounds J. Allergy Clin. Immunol. 58 6 1976 691 712
20. J.R. Vane Prostaglandins as mediators of inflammation Adv. Prostaglandin Thromboxane Res. 2 1976 791 801
21. M.K. O'Banion, V.D. Winn, and D.A. Young cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase Proc. Natl. Acad. Sci. USA 89 11 1992 4888 4892
22. M.K. O'Banion Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology Crit. Rev. Neurobiol. 13 1 1999 45 82
23. M.K. O'Banion, and J.A. Olschowka Localization and distribution of cyclooxygenase-2 in brain tissue by immunohistochemistry Methods Mol. Biol. 120 1999 55 66
24. B. Samuelsson The leukotrienes: an introduction Adv. Prostaglandin Thromboxane Leukot. Res. 9 1982 1 17
25. C.N. Serhan, and J.M. Drazen Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? J. Clin. Invest. 99 6 1997 1147 1148
26. C.D. Funk Prostaglandins and leukotrienes: advances in eicosanoid biology Science 294 5548 2001 1871 1875
27. C. Bandeira-Melo, P.T. Bozza, and P.F. Weller The cellular biology of eosinophil eicosanoid formation and function J. Allergy Clin. Immunol. 109 3 2002 393 400
28. C.N. Serhan A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: missing links to resolution Histochem. Cell Biol. 122 4 2004 305 321
29. J.P. Rivers, and T.L. Frankel Essential fatty acid deficiency Br. Med. Bull. 37 1 1981 59 64
30. A.H. Lichtenstein Efficacy of a therapeutic lifestyle change/step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects J. Lipid Res. 43 2 2002 264 273
31. T.L. Frankel, and J.P. Rivers The nutritional and metabolic impact of gamma-linolenic acid (18:3omega6) on cats deprived of animal lipid Br. J. Nutr. 39 1 1978 227 231
32. D. Lanzmann-Petithory, S. Pueyo, and S. Renaud Primary prevention of cardiovascular diseases by alpha-linolenic acid Am. J. Clin. Nutr. 76 6 2002 1456 author reply 1456-7
33. D. Lanzmann-Petithory Alpha-linolenic acid and cardiovascular diseases J. Nutr. Health Aging 5 3 2001 179 183
34. Y. Goto, H. Tamachi, and E.H. Moriguchi Eicosapentaenoic acid and atherosclerosis Prostaglandins Leukot. Essent. Fatty Acids 48 5 1993 337 342
35. M.E. Turini, and R.N. DuBois Cyclooxygenase-2: a therapeutic target Annu. Rev. Med. 53 2002 35 57
36. S. Offenbacher Periodontal infection as a possible risk factor for preterm low birth weight J. Periodontol. 67 10 Suppl 1996 1103 1113
37. S. Offenbacher Maternal periodontitis and prematurity. Part I: obstetric outcome of prematurity and growth restriction Ann. Periodontol. 6 1 2001 164 174
38. P.N. Madianos Maternal periodontitis and prematurity. Part II: maternal infection and fetal exposure Ann. Periodontol. 6 1 2001 175 182
39. J.D. Beck, and S. Offenbacher The association between periodontal diseases and cardiovascular diseases: a state-of-the-science review Ann. Periodontol. 6 1 2001 9 15
40. J. Vane, and R. Botting Inflammation and the mechanism of action of anti-inflammatory drugs FASEB J. 1 2 1987 89 96
41. J.R. Vane, and R.M. Botting Mechanism of action of anti-inflammatory drugs Adv. Exp. Med. Biol. 433 1997 131 138
42. J.R. Vane, and R.M. Botting Mechanism of action of nonsteroidal anti-inflammatory drugs Am. J. Med. 104 3A 1998 2S 8S discussion 21S-22S
43. R.J. Flower Studies on the mechanism of action of anti-inflammatory drugs. A paper in honour of John Vane Thromb. Res. 110 5-6 2003 259 263
44. B. Samuelsson Leukotrienes and lipoxins: structures, biosynthesis, and biological effects Science 237 4819 1987 1171 1176
45. J.M. Drazen, E. Israel, and P.M. O'Byrne Treatment of asthma with drugs modifying the leukotriene pathway N. Engl. J. Med. 340 3 1999 197 206
46. L.M. Jackson, and C.J. Hawkey COX-2 selective nonsteroidal anti-inflammatory drugs: do they really offer any advantages? Drugs 59 6 2000 1207 1216
47. M. Mamdani Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly Arch. Intern. Med. 163 4 2003 481 486
48. L.J. Mengle-Gaw, and B.D. Schwartz Cyclooxygenase-2 inhibitors: promise or peril? Mediat. Inflamm. 11 5 2002 275 286
49. C.N. Serhan, and K.A. Sheppard Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro J. Clin. Invest. 85 3 1990 772 780
50. C.N. Serhan, S. Fiore, and B.D. Levy Cell-cell interactions in lipoxin generation and characterization of lipoxin A4 receptors Ann. NY Acad. Sci. 744 1994 166 180
51. B.D. Levy Lipid mediator class switching during acute inflammation: signals in resolution Nat. Immunol. 2 7 2001 612 619
52. H.R. Brady, and C.N. Serhan Lipoxins: putative braking signals in host defense, inflammation and hypersensitivity Curr. Opin. Nephrol. Hypertens. 5 1 1996 20 27
53. C.N. Serhan, M. Hamberg, and B. Samuelsson Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes Proc. Natl. Acad. Sci. USA 81 17 1984 5335 5339
54. K.F. Badr Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor Proc. Natl. Acad. Sci. USA 86 9 1989 3438 3442
55. T.H. Lee Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure-function relationships Biochem. Biophys. Res. Commun. 180 3 1991 1416 1421
56. C.N. Serhan, and M. Romano Lipoxin biosynthesis and actions: role of the human platelet LX-synthase J. Lipid Mediat. Cell Signal. 12 2-3 1995 293 306
57. M.E. Brezinski, and C.N. Serhan Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: agonist-induced deacylation and transformation of stored hydroxyeicosanoids Proc. Natl. Acad. Sci. USA 87 16 1990 6248 6252
58. J. Claria, and C.N. Serhan Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions Proc. Natl. Acad. Sci. USA 92 21 1995 9475 9479
59. S. Fiore, and C.N. Serhan Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction Biochemistry 34 51 1995 16678 16686
60. M. Romano Lipoxin synthase activity of human platelet 12-lipoxygenase Biochem. J. 296 Pt 1 1993 127 133
61. T.N. Mayadas Acute passive anti-glomerular basement membrane nephritis in P-selectin-deficient mice Kidney Int. 49 5 1996 1342 1349
62. A. Papayianni Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis Kidney Int. 47 5 1995 1295 1302
63. C.N. Serhan Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils Biochemistry 34 44 1995 14609 14615
64. B.D. Levy, J.M. Drazen, and C.N. Serhan Agonist-induced lipoxin A4 generation in vitro and in aspirin-sensitive asthmatics: detection by a novel lipoxin A4-ELISA Adv. Exp. Med. Biol. 400B 1997 611 615
65. B.S. Reddy, C.V. Rao, and K. Seibert Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis Cancer Res. 56 20 1996 4566 4569
66. R.N. DuBois, F.M. Giardiello, and W.E. Smalley Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention Gastroenterol. Clin. North Am. 25 4 1996 773 791
67. S. Fiorucci A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction Proc. Natl. Acad. Sci. USA 101 44 2004 15736 15741
68. S. Fiorucci Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence J. Pharmacol. Exp. Ther. 309 3 2004 1174 1182
69. S. Fiorucci Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa Proc. Natl. Acad. Sci. USA 100 19 2003 10937 10941
70. S. Fiorucci Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin Br. J. Pharmacol. 139 7 2003 1351 1359
71. S. Fiorucci Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage Gastroenterology 123 5 2002 1598 1606
72. J.L. Wallace Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats Gastroenterology 117 3 1999 557 566
73. A. Kantarci, and T.E. Van Dyke Lipoxins in chronic inflammation Crit. Rev. Oral Biol. Med. 14 1 2003 4 12
74. J. Aliberti, C. Serhan, and A. Sher Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection J. Exp. Med. 196 9 2002 1253 1262
75. T.E. Van Dyke, and C.N. Serhan Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases J. Dent. Res. 82 2 2003 82 90
76. C. Nathan Points of control in inflammation Nature 420 6917 2002 846 852
77. O. Levy Expression of BPI (bactericidal/permeability-increasing protein) in human mucosal epithelia Biochem. Soc. Trans. 31 Pt 4 2003 795 800
78. G. Majno Inflammation and infection: historic highlights Monogr. Pathol. 23 1982 1 17
79. C.N. Serhan Eicosanoids in leukocyte function Curr. Opin. Hematol. 1 1 1994 69 77
80. C.N. Serhan Lipoxin biosynthesis and its impact in inflammatory and vascular events Biochim. Biophys. Acta 1212 1 1994 1 25
81. C.N. Serhan, and S. Fiore Lipoxin recognition sites of human neutrophils Adv. Prostaglandin Thromboxane Leukot. Res. 22 1994 317 326
82. C.B. Clish Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo Proc. Natl. Acad. Sci. USA 96 14 1999 8247 8252
83. N. Chiang A novel rat lipoxin A4 receptor that is conserved in structure and function Br. J. Pharmacol. 139 1 2003 89 98
84. P.R. Devchand Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense FASEB J. 17 6 2003 652 659
85. M. Hachicha Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis J. Exp. Med. 189 12 1999 1923 1930
86. A.T. Gewirtz Pathogen-induced chemokine secretion from model intestinal epithelium is inhibited by lipoxin A4 analogs J. Clin. Invest. 101 9 1998 1860 1869
87. K. Gronert Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release J. Exp. Med. 187 8 1998 1285 1294
88. S. Mitchell Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo J. Am. Soc. Nephrol. 13 10 2002 2497 2507
89. C. Chavis Formation of lipoxins and leukotrienes by human alveolar macrophages incubated with 15(S)-HETE: a model for cellular cooperation between macrophages and airway epithelial cells Eicosanoids 5 3-4 1992 203 211
90. D.A. Brezinski, R.W. Nesto, and C.N. Serhan Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy Circulation 86 1 1992 56 63
91. L. Stenke, P. Reizenstein, and J.A. Lindgren Leukotrienes and lipoxins - new potential performers in the regulation of human myelopoiesis Leuk. Res. 18 10 1994 727 732
92. N. Chiang Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA J. Pharmacol. Exp. Ther. 287 2 1998 779 790
93. M. Sanak Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics Eur. Respir. J. 16 1 2000 44 49
94. L. Stenke Lipoxygenase products in myeloproliferative disorders: increased leukotriene C4 and decreased lipoxin formation in chronic myeloid leukemia Adv. Prostaglandin Thromboxane Leukot. Res. 21B 1991 883 886
95. J. Claria Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites Gastroenterology 115 1 1998 147 156
96. L. Stenke Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia Blood 78 11 1991 2989 2995
97. T.E. Van Dyke Neutrophil function in localized juvenile periodontitis. Phagocytosis, superoxide production and specific granule release J. Periodontol. 57 11 1986 703 708
98. S. Offenbacher, B.M. Odle, and T.E. Van Dyke The use of crevicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss J. Periodontal. Res. 21 2 1986 101 112
99. M. Pouliot Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease Biochemistry 39 16 2000 4761 4768
100. S. Offenbacher Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients J. Periodontal. Res. 19 1 1984 1 13
101. C.C. Tsai Measurement of prostaglandin E2 and leukotriene B4 in the gingival crevicular fluid J. Dent. 26 2 1998 97 103
102. T.M. ElAttar, H.S. Lin, and D.E. Tira Testosterone inhibits prostaglandin formation by human gingival connective tissue: relationship to 14C-arachidonic acid metabolism Prostaglandins Leukot. Med. 9 1 1982 25 34
103. T.M. ElAttar Prostaglandin E2 in human gingiva in health and disease and its stimulation by female sex steroids Prostaglandinss 11 2 1976 331 341
104. T.M. ElAttar Hydroxy fatty acids and prostaglandin formation in diseased human periodontal pocket tissue J. Periodontal. Res. 21 2 1986 169 176
105. T.M. ElAttar, and H.S. Lin Prostaglandin E2 antagonizes gingival fibroblast proliferation stimulated by interleukin-1 beta Prostaglandins Leukot. Essent. Fatty Acids 49 5 1993 847 850
106. C.N. Serhan Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators J. Immunol. 171 12 2003 6856 6865